Saturday, February 7, 2026
StockstToday.com Logo
  • Home
  • Tech & Software
  • Earnings
  • Analysis
  • Trading & Momentum
  • Cryptocurrency
  • Banking & Insurance
  • AI & Quantum Computing
No Result
View All Result
  • Home
  • Tech & Software
  • Earnings
  • Analysis
  • Trading & Momentum
  • Cryptocurrency
  • Banking & Insurance
  • AI & Quantum Computing
No Result
View All Result
StocksToday.com Logo
No Result
View All Result
Home Breaking News

LifeMD Receives Buy Rating with Increased Price Target

Elaine Mendonca by Elaine Mendonca
March 12, 2024
in Breaking News
0
0
SHARES
9
VIEWS
Share on FacebookShare on Twitter

According to Craig-Hallum analyst Alex Fuhrman, LifeMD (NASDAQ: LFMD) continues to receive a Buy rating, with the price target now increased to $15 from $10. This adjustment is a result of a positive outlook on the company’s performance.

_____

Looking ahead to the next 12 months, the average stock price forecast for LifeMD is $9.00, with expectations of a 15.09% increase. The highest forecast is even more optimistic at $12. Overall, analysts are rating LifeMD stock as a strong buy, suggesting a promising future ahead.

_____

As of March 12, 2024, investors are encouraged by the potential growth prospects of LifeMD.

LFMD Stock Shows Strong Performance on March 12, 2024: Positive Momentum and Price Increase

On March 12, 2024, LFMD stock showed strong performance as it traded near the top of its 52-week range and above its 200-day simple moving average. The stock opened at $8.25, which was $0.30 higher than its previous close, indicating positive momentum right from the start of the trading day.

Throughout the day, LFMD shares continued to rise, with a price increase of $0.55 since the market last closed. This represented a significant 6.92% increase in the stock price, showing strong bullish movement and investor confidence in the company.

The strong performance of LFMD on March 12 can be attributed to a variety of factors, including positive market sentiment, favorable industry trends, or company-specific news or developments. Investors may have been reacting to positive earnings reports, new product launches, or other positive announcements from the company.

Overall, LFMD stock showed impressive performance on March 12, with a significant price increase and strong momentum throughout the trading day. Investors will be closely watching to see if this positive trend continues in the days and weeks ahead.

LFMD Stock Shows Promising Performances with Strong Financial Results in 2024

On March 12, 2024, LFMD stock showed promising performances as the company reported solid financial results. According to data from CNN Money, LFMD’s total revenue for the past year was $119.03 million, which represented a 28.16% increase compared to the previous year. In the third quarter alone, the company generated $38.61 million in revenue, marking a 7.42% increase from the previous quarter.

Net income for LFMD also saw positive growth, with a net loss of $45.53 million for the year, which was a 25.23% improvement from the previous year. In the third quarter, the company reported a net loss of $6.12 million, representing a 9.07% increase from the previous quarter.

Earnings per share (EPS) for LFMD showed significant improvement as well. The company reported an EPS of -$1.57 for the year, which was a 31.34% increase from the previous year. In the third quarter, the EPS was -$0.20, showing a 13.23% increase from the previous quarter.

Tags: LFMD
Elaine Mendonca

Elaine Mendonca

Related Posts

NFT projects
Breaking News

The Impact of TikToks Fate on USChina Relations and American Tech Giants

March 16, 2024
Businesses finance
Breaking News

Blackstone Strategic Credit 2027 Term Fund BGB Announces Monthly Dividend of 93 Cents per Share

March 15, 2024
Healthcare-sector
Breaking News

Analyzing Short Interest in Molina Healthcare Inc MOH

March 15, 2024
Next Post
Finances-and-tech

Accentures Stock Price Targets Continue to Rise

Unlocking Value: The Economic Potential of Iron-Titanium-Vanadium Projects

Goldman Sachs Analyst Reaffirms Sell Rating on Franklin Resources

Healthcare Services Stock Exchange

Universal Health Services NYSE UHS Upgraded to Sector Perform with Increased Price Target

Recommended

Gold Stock

Gold Nears Historic Peak as Market Anticipation Builds

2 months ago
Dentist

Advancements in Oral Healthcare: The Business Impact of Highly Trained Surgeons

2 years ago
Archer Aviation Stock

Archer Aviation Strengthens Market Position Through Strategic Patent Acquisition

4 months ago
SNDR stock news

Yousif Capital Management LLC Reduces Stake in Steven Madden, Ltd.: Implications for the Company’s Future Performance

3 years ago

Categories

  • AI & Quantum Computing
  • Analysis
  • Analyst Ratings
  • Asian Markets
  • Automotive & E-Mobility
  • Banking & Insurance
  • Bitcoin
  • Blockchain
  • Bonds
  • Breaking News
  • Business & Industry Trends
  • Cannabis
  • Chemicals
  • Commodities
  • Consumer & Luxury
  • Crypto Stocks
  • Cryptocurrency
  • Cyber Security
  • DAX
  • Defense & Aerospace
  • Dividends
  • Dow Jones
  • E-Commerce
  • Earnings
  • Emerging Markets
  • Energy & Oil
  • ETF
  • Ethereum & Altcoins
  • European Markets
  • Forex
  • Gaming & Metaverse
  • Gold & Precious Metals
  • Healthcare
  • Hydrogen
  • Index
  • Industrial
  • Insider Trading
  • IPOs
  • Market Commentary
  • Market News
  • MDAX & SDAX
  • Mergers & Acquisitions
  • Nasdaq
  • Newsletter
  • Penny Stocks
  • Pharma & Biotech
  • Real Estate & REITs
  • Renewable Energy
  • S&P 500
  • Semiconductors
  • Space
  • Stock Picks
  • Stock Targets
  • Stocks
  • TecDAX
  • Tech & Software
  • Telecommunications
  • Trading & Momentum
  • Turnaround
  • Uncategorized
  • Value & Growth

Topics

Adobe Alibaba Alphabet Amazon AMD Apple ASML BioNTech Bitcoin Broadcom Coca-Cola Coinbase D-Wave Quantum Eli Lilly Fiserv IBM Intel Kraft Heinz Marvell Technology META Micron Microsoft MP Materials MSCI World ETF Newmont Mining NIO Novo Nordisk Nvidia Ocugen Opendoor Oracle Palantir PayPal Plug Power QuantumScape Robinhood Rocket Lab USA Strategy Super Micro Computer Synopsys Tesla Tilray Unitedhealth Uranium Energy Viking Therapeutics
No Result
View All Result

Highlights

Amazon’s $200 Billion Penalty, The Bad News Rally, and A Cloud Divorce

Graftech Shares Plunge on Bleak Quarterly Results

Potbelly Accelerates Northeast Growth with New Jersey Franchise Push

Conduent Faces Mounting Fallout from Major Data Breach Ahead of Earnings

Blue Ridge Bankshares Emerges from Regulatory Challenges with Return to Profitability

Navigating the Interest Rate Tightrope: Bank7’s Path Forward

Trending

Design Therapeutics Stock
Analysis

Design Therapeutics Approaches Key Clinical Milestones with Ample Funding

by Rodolfo Hanigan
February 7, 2026
0

Investor attention is turning to the upcoming catalysts for Design Therapeutics, a biotechnology firm advancing its GeneTAC...

Vigil Neuroscience Stock

Sanofi Completes Vigil Neuroscience Acquisition, Eyes Alzheimer’s Therapy

February 7, 2026
Repay Holdings Stock

Repay Holdings: Annual Report to Test Strategic Refinancing Success

February 7, 2026
Amazon’s $200 Billion Penalty, The Bad News Rally, and A Cloud Divorce

Amazon’s $200 Billion Penalty, The Bad News Rally, and A Cloud Divorce

February 7, 2026
Graftech Stock

Graftech Shares Plunge on Bleak Quarterly Results

February 7, 2026

StocksToday.com is your one-stop destination for the latest stock news and analysis. We provide in-depth coverage of the stock market, including market news, company news, sector news, IPO news, investment strategies, personal finance, international markets, and more.

Follow us on social media:

Recent News

  • Design Therapeutics Approaches Key Clinical Milestones with Ample Funding
  • Sanofi Completes Vigil Neuroscience Acquisition, Eyes Alzheimer’s Therapy
  • Repay Holdings: Annual Report to Test Strategic Refinancing Success

Category

  • About
  • Advertise
  • Careers
  • Contact
  • Imprint
  • Privacy Policy
  • Terms of Service

© 2023 StocksToday.com

No Result
View All Result
  • Home
  • Tech & Software
  • Earnings
  • Analysis
  • Trading & Momentum
  • Cryptocurrency
  • Banking & Insurance
  • AI & Quantum Computing

© 2023 StocksToday.com